Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Efforts to Improve Quality of Migraine Care
    Release Date:
    Partner: The Japanese Headache Society
    Review Process: Expert Review Panel
    Translation: Japanese (link)
    Quality Improvement Internal Medicine Japan
    Enhancing HCP Education in Adult Vaccination against Respiratory Infections
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Austria, Belgium, Greece, Ireland, Luxembourg, Portugal, Switzerland
    Migraine and Women’s Health
    Release Date:
    Partner: American Headache Society
    Review Process: Expert Review Panel
    Quality Improvement, Research Internal Medicine USA
    Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)
    Release Date:
    Review Process: Pfizer Internal
    Research Rare Disease USA
    Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI)
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology All
    Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) - Education for Healthcare Professionals
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA
    Prostate Cancer: Best Practices for Combining Targeted Therapies in mPC
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Transthyretin Cardiac Amyloidosis Fellowship
    Release Date:
    Review Process: Expert Review Panel
    Research Rare Disease USA
    Optimizing Adult Vaccination Ecosystem in India
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines India
    Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic Dermatitis
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Spain
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Transition of Care in VTE
    Release Date:
    Anticoagulation Education - NVAF or VTE
    Release Date:
    Review Process:
    Achievement of Treat-to-Target in Rheumatoid Arthritis
    Release Date:
    Improving Care of Chronic Pain- Physician Groups and Health Systems
    Release Date:
    Facilitation of the Diagnosis of Rheumatoid Arthritis
    Release Date:
    Pfizer and NCCN: Metastatic Breast Cancer
    Release Date:
    Pediatric Immunization Series Completion
    Release Date:
    Pfizer and National Psoriasis Foundation (NPF): Plugging the Treatment Gap in Psoriasis and Psoriatic Arthritis
    Release Date:
    Pfizer and International Atherosclerosis Society (IAS): Lipid Management in High-Risk Patients
    Release Date:
    Pfizer and American Academy of Dermatology (AAD): Patient Access to Care
    Release Date:
    Narrowing the Time Gap between Onset of Symptoms and Treatment for Rheumatoid Arthritis
    Release Date: